menu
    • menu
    [{"orgOrder":0,"company":"Lodo Therapeutics","sponsor":"Hibiskus BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"TIR-199","moa":"Syrbactin proteasome","graph1":"Oncology","graph2":"Preclinical","graph3":"Lodo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lodo Therapeutics \/ Lodo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lodo Therapeutics \/ Lodo Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Lodo Therapeutics

    Menu

    Lodo Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lodo Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Lodo Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TIR-199

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Hibiskus BioPharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lodo Therapeutics Acquires Hibiskus Biopharma AND Licenses Rights to Novel Proteasome Inhibitors

                            Details : With this acquisition, Lodo expands its preclinical pipeline with selective proteasome inhibitors with potential application in solid tumor cancers and other indications. Logo gains exclusive license to intellectual property from university of california...

                            Brand Name : LODO-141

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            September 03, 2020

                            Lead Product(s) : TIR-199

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Hibiskus BioPharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth